ABSTRACT Methotrexate by intermittent intramuscular injection was used to treat three patients with fibrosing alveolitis complicating connective tissue diseases. All three patients had improvement of symptoms, two had radiological improvement, and one had significant improvement of pulmonary function. Two 
Fibrosing alveolitis is a well-recognised complication of rheumatoid arthritis, polymyositis, and other connective tissue diseases. It is difficult to treat and carries a poor prognosis.' Conventional treatment with corticosteroids has been disappointing but more recent reports of immunosuppressive therapy, including azathioprine and cyclophosphamide, have been more encouraging. We have treated three patients with intramuscular methotrexate and report our findings.
Methods
Three patients with fibrosing alveolitis complicating connective tissue diseases were studied before and during methotrexate treatment. They were followed for a period ranging from 11 months to two years. Clinical assessments, chest radiographs, and pulmonary function tests were carried out before and at regular intervals during treatment. A diagnosis of fibrosing alveolitis was based on breathlessness, persistent late inspiratory basal crackles, typical chest radiographic appearances, and restrictive lung function tests with reduced gas transfer. Methotrexate was chosen initially because of an encouraging response of lung function when it was used to treat a case of polymyositis (see case 1) . One Methotrexate caused severe oral candidiasis in one patient, which responded promptly to dose reduction. Two patients developed pneumonias which were of bacterial origin and not associated with neutropenia. There was no suggestion of drug-induced pneumonitis and no hepatotoxicity.
Discussion
Fibrosing alveolitis describes a pathological response in the lung without implying causation. Some aetiological agents are recognised but in most cases the primary cause remains unknown. It occurs in association with connective tissue diseases and some patients with cryptogenic fibrosing alveolitis carry immunological markers of these disorders such as rheumatoid factor and antinuclear antibody.3 The importance of immunological mechanisms in aetiology is suggested by the presence of immunoglobulin and sometimes complement along alveolar walls and capillaries, and the presence in the blood of immune complexes in patients with active interstitial disease. This has been found both in cryptogenic fibrosing alveolitis4 5 and that complicating rheumatoid arthritis.5 a
Progress from interstitial infiltration with inflammatory cells to terminal fibrosis is implicit in the many terms used to describe fibrosing alveolitis (diffuse interstitial pneumonitis, pulmonary fibrosis and so on). It is hardly surprising that patients with extensive fibrosis respond less well to treatment than those with earlier active inflammatory changes. Prognosis and response to treatment are said to be improved in patients with prominent desquamation of alveolar cells rather than the more usual interstitial inflammatory infiltration.7 They are also better in younger patients' and those with a shorter history of lung disease.8 Those with evidence of circulating immune complexes respond better to treatment with corticosteriods.4 A more practical approach has been to assess the response to corticosteriods (the currently described treatment of choice), in order to avoid the procedure of lung biopsy except in patients with atypical features and where the diagnosis is in some doubt. 
